{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:31:18Z","timestamp":1792017078249,"version":"4.4.0"},"reference-count":150,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T00:00:00Z","timestamp":1666656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Health &amp; Social Care","award":["EP\/R013764\/1"],"award-info":[{"award-number":["EP\/R013764\/1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Rift Valley fever (RVF) is a mosquito-borne viral zoonosis that causes high fetal and neonatal mortality in ruminants and a mild to fatal hemorrhagic fever in humans. There are no licensed RVF vaccines for human use while for livestock, commercially available vaccines are all either live attenuated or inactivated and have undesirable characteristics. The live attenuated RVF vaccines are associated with teratogenicity and residual virulence in ruminants while the inactivated ones require multiple immunisations to induce and maintain protective immunity. Additionally, nearly all licensed RVF vaccines lack the differentiating infected from vaccinated animals (DIVA) property making them inappropriate for use in RVF nonendemic countries. To address these limitations, novel DIVA-compatible RVF vaccines with better safety and efficacy than the licensed ones are being developed, aided fundamentally by a better understanding of the molecular biology of the RVF virus and advancements in recombinant DNA technology. For some of these candidate RVF vaccines, sterilizing immunity has been demonstrated in the discovery\/feasibility phase with minimal adverse effects. This review highlights the progress made to date in RVF vaccine research and development and discusses the outstanding research gaps.<\/jats:p>","DOI":"10.3390\/vaccines10111794","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T11:53:51Z","timestamp":1666785231000},"page":"1794","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["An Overview of Rift Valley Fever Vaccine Development Strategies"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9038-8074","authenticated-orcid":false,"given":"Paul Kato","family":"Kitandwe","sequence":"first","affiliation":[{"name":"MRC\/UVRI & LSHTM Uganda Research Unit, Entebbe 31410, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5195-6254","authenticated-orcid":false,"given":"Paul F.","family":"McKay","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Division of Medicine, Imperial College London, Norfolk Place, London W2 1PG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontiano","family":"Kaleebu","sequence":"additional","affiliation":[{"name":"MRC\/UVRI & LSHTM Uganda Research Unit, Entebbe 31410, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin J.","family":"Shattock","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Division of Medicine, Imperial College London, Norfolk Place, London W2 1PG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/path.1700340418","article-title":"Enzootic hepatitis or Rift Valley fever. An undescribed virus disease of sheep cattle and man from East Africa","volume":"34","author":"Daubney","year":"1931","journal-title":"J. Pathol. Bacteriol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1099\/jgv.0.001296","article-title":"Rift Valley fever: Biology and epidemiology","volume":"100","author":"Wright","year":"2019","journal-title":"J. Gen. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jmv.21132","article-title":"Case report: Rift Valley fever with vertical transmission in a pregnant Sudanese woman","volume":"80","author":"Adam","year":"2008","journal-title":"J. Med. Virol."},{"key":"ref_4","first-page":"287","article-title":"Co-housing of Rift Valley fever virus infected lambs with immunocompetent or immunosuppressed lambs does not result in virus transmission","volume":"7","author":"Kant","year":"2016","journal-title":"Front. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2460\/ajvr.71.5.522","article-title":"Identification of potential vectors of and detection of antibodies against Rift Valley fever virus in livestock during interepizootic periods","volume":"71","author":"Rostal","year":"2010","journal-title":"Am. J. Vet. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1017\/S0950268810001020","article-title":"Rift Valley fever in Kenya: History of epizootics and identification of vulnerable districts","volume":"139","author":"Murithi","year":"2010","journal-title":"Epidemiol. Infect."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.antiviral.2012.06.001","article-title":"Molecular biology and genetic diversity of Rift Valley fever virus","volume":"95","author":"Ikegami","year":"2012","journal-title":"Antivir. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1086\/378747","article-title":"Rift Valley fever epidemic in Saudi Arabia: Epidemiological, clinical, and laboratory characteristics","volume":"37","author":"Madani","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Samy, A.M., Peterson, A.T., and Hall, M. (2017). Phylogeography of Rift Valley fever virus in Africa and the Arabian Peninsula. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005226"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Paweska, J.T., and van Vuren, P.J. (2014). Rift Valley fever virus: A virus with potential for global emergence. The Role of Animals in Emerging Viral Diseases, Elsevier.","DOI":"10.1016\/B978-0-12-405191-1.00008-9"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4172\/2157-2526.1000108","article-title":"Rift Valley fever virus: A real bioterror threat","volume":"2","author":"Mandell","year":"2011","journal-title":"J. Bioterrorism Biodefense"},{"key":"ref_12","unstructured":"Animal and Plant Health Inspection Service, and U.S Department of Agriculture (2022, October 20). OIE and International Standards, Available online: https:\/\/www.aphis.usda.gov\/aphis\/ourfocus\/animalhealth\/nvap\/NVAP-Reference-Guide\/Animal-Health-Emergency-Management\/OIE-and-International-Standards."},{"key":"ref_13","unstructured":"Federal Select Agent Program, Centers for Disease Control and Prevention, and The United States Department of Agriculture (2022, October 20). Select Agents and Toxins List, Available online: https:\/\/www.selectagents.gov\/sat\/list.htm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1017\/S0950268807009806","article-title":"Prevalence of antibodies against Rift Valley fever virus in Kenyan wildlife","volume":"136","author":"Evans","year":"2008","journal-title":"Epidemiol. Infect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.20506\/rst.34.2.2364","article-title":"Rift Valley fever","volume":"34","author":"Paweska","year":"2015","journal-title":"Rev. Sci. Tech."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cll.2017.01.004","article-title":"Rift valley fever","volume":"37","author":"Hartman","year":"2017","journal-title":"Clin. Lab. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/v3050493","article-title":"The pathogenesis of Rift Valley fever","volume":"3","author":"Ikegami","year":"2011","journal-title":"Viruses"},{"key":"ref_18","unstructured":"World Health Organization (2008). Rift Valley fever fact sheet:(Revised in September 2007). Wkly. Epidemiol. Rec. Relev. \u00c9pid\u00e9miologique Hebd., 83, 17\u201322."},{"key":"ref_19","first-page":"8","article-title":"Molecular biology of Rift Valley fever virus","volume":"4","author":"Bouloy","year":"2010","journal-title":"Open Virol. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1128\/jvi.69.7.3972-3979.1995","article-title":"The L protein of Rift Valley fever virus can rescue viral ribonucleoproteins and transcribe synthetic genome-like RNA molecules","volume":"69","author":"Lopez","year":"1995","journal-title":"J. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1128\/JVI.02148-08","article-title":"NSs protein of rift valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase","volume":"83","author":"Habjan","year":"2009","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Ikegami, T., Narayanan, K., Won, S., Kamitani, W., Peters, C.J., and Makino, S. (2009). Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000287"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6234","DOI":"10.1128\/JVI.02255-10","article-title":"NSs protein of rift valley fever virus promotes posttranslational downregulation of the TFIIH subunit p62","volume":"85","author":"Kalveram","year":"2011","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9798","DOI":"10.1128\/JVI.78.18.9798-9806.2004","article-title":"NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription","volume":"78","author":"Billecocq","year":"2004","journal-title":"J. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1128\/JVI.75.3.1371-1377.2001","article-title":"Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs","volume":"75","author":"Bouloy","year":"2001","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2013.09.023","article-title":"Role of the cytosolic tails of Rift Valley fever virus envelope glycoproteins in viral morphogenesis","volume":"448","author":"Carnec","year":"2014","journal-title":"Virology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"13335","DOI":"10.1128\/JVI.01238-07","article-title":"NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis","volume":"81","author":"Won","year":"2007","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Weingartl, H.M., Zhang, S., Marszal, P., McGreevy, A., Burton, L., and Wilson, W.C. (2014). Rift Valley fever virus incorporates the 78 kDa glycoprotein into virions matured in mosquito C6\/36 cells. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0087385"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.chom.2011.06.007","article-title":"DC-SIGN as a receptor for phleboviruses","volume":"10","author":"Lozach","year":"2011","journal-title":"Cell Host Microbe"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Phoenix, I., Nishiyama, S., Lokugamage, N., Hill, T., Huante, M., Slack, O., Carpio, V., Freiberg, A., and Ikegami, T. (2016). N-glycans on the Rift Valley fever virus envelope glycoproteins Gn and Gc redundantly support viral infection via DC-SIGN. Viruses, 8.","DOI":"10.3390\/v8050149"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"12954","DOI":"10.1128\/JVI.02242-12","article-title":"Rift Valley fever virus strain MP-12 enters mammalian host cells via caveola-mediated endocytosis","volume":"86","author":"Harmon","year":"2012","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"13642","DOI":"10.1128\/JVI.01973-12","article-title":"Acid-activated structural reorganization of the Rift Valley fever virus Gc fusion protein","volume":"86","author":"Kortekaas","year":"2012","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1099\/0022-1317-75-6-1345","article-title":"Rift Valley fever virus L segment: Correction of the sequence and possible functional role of newly identified regions conserved in RNA-dependent polymerases","volume":"75","author":"Poch","year":"1994","journal-title":"J. Gen. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41541-020-0166-9","article-title":"Rift Valley fever virus vaccination induces long-lived, antigen-specific human T cell responses","volume":"5","author":"Harmon","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_35","first-page":"65","article-title":"Rift valley fever","volume":"10","author":"Easterday","year":"1965","journal-title":"Adv. Vet. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Faburay, B., LaBeaud, A.D., McVey, D.S., Wilson, W.C., and Richt, J.A. (2017). Current status of Rift Valley fever vaccine development. Vaccines, 5.","DOI":"10.3390\/vaccines5030029"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1051\/vetres\/2010033","article-title":"Rift Valley fever virus (Bunyaviridae: Phlebovirus): An update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention","volume":"41","author":"Pepin","year":"2010","journal-title":"Vet. Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Xu, W., Watts, D.M., Costanzo, M.C., Tang, X., Venegas, L.A., Jiao, F., Sette, A., Sidney, J., Sewell, A.K., and Wooldridge, L. (2013). The nucleocapsid protein of Rift Valley fever virus is a potent human CD8+ T cell antigen and elicits memory responses. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0059210"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Jansen van Vuren, P., Tiemessen, C.T., and Paweska, J.T. (2011). Anti-nucleocapsid protein immune responses counteract pathogenic effects of Rift Valley fever virus infection in mice. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025027"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e01662-17","DOI":"10.1128\/JVI.01662-17","article-title":"Peripheral Blood Biomarkers of Disease Outcome in a Monkey Model of Rift Valley Fever Encephalitis","volume":"92","author":"Wonderlich","year":"2018","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.virol.2011.09.023","article-title":"Rift Valley fever virus inhibits a pro-inflammatory response in experimentally infected human monocyte derived macrophages and a pro-inflammatory cytokine response may be associated with patient survival during natural infection","volume":"422","author":"McElroy","year":"2012","journal-title":"Virology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1080\/14712598.2019.1662784","article-title":"Candidate vaccines for human Rift Valley fever","volume":"19","author":"Ikegami","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7346294","DOI":"10.1155\/2016\/7346294","article-title":"Safety and Efficacy Profile of Commercial Veterinary Vaccines against Rift Valley Fever: A Review Study","volume":"2016","author":"Alhaj","year":"2016","journal-title":"J. Immunol. Res."},{"key":"ref_44","first-page":"1","article-title":"Rift Valley fever: The neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine","volume":"30","author":"Smithburn","year":"1949","journal-title":"Br. J. Exp. Pathol."},{"key":"ref_45","first-page":"107","article-title":"Rift Valley fever; isolation of the virus from wild mosquitoes","volume":"29","author":"Smithburn","year":"1948","journal-title":"Br. J. Exp. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1016\/j.vaccine.2011.05.055","article-title":"Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves","volume":"29","author":"Engelbrecht","year":"2011","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1177\/10406387211015294","article-title":"Vaccination with Rift Valley fever virus live attenuated vaccine strain Smithburn caused meningoencephalitis in alpacas","volume":"33","author":"Anthony","year":"2021","journal-title":"J. Vet. Diagn. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/jmv.20624","article-title":"Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine","volume":"78","author":"Botros","year":"2006","journal-title":"J. Med. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1743-422X-6-94","article-title":"Pathological studies on postvaccinal reactions of Rift Valley fever in goats","volume":"6","author":"Kamal","year":"2009","journal-title":"Virol. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.coviro.2018.02.001","article-title":"Rift Valley fever vaccines: Current and future needs","volume":"29","author":"Dungu","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3201\/eid1712.111035","article-title":"Molecular epidemiology of Rift Valley fever virus","volume":"17","author":"Grobbelaar","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-1702(97)00097-X","article-title":"Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation","volume":"52","author":"Vialat","year":"1997","journal-title":"Virus Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0264-410X(91)90314-V","article-title":"Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep","volume":"9","author":"Morrill","year":"1991","journal-title":"Vaccine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.vetmic.2014.04.007","article-title":"Evaluation of lamb and calf responses to Rift Valley fever MP-12 vaccination","volume":"172","author":"Wilson","year":"2014","journal-title":"Vet. Microbiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1128\/CVI.00114-15","article-title":"Evaluation of the Efficacy, Potential for Vector Transmission, and Duration of Immunity of MP-12, an Attenuated Rift Valley Fever Virus Vaccine Candidate, in Sheep","volume":"22","author":"Miller","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2460\/ajvr.1997.58.10.1104","article-title":"Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle","volume":"58","author":"Morrill","year":"1997","journal-title":"Am. J. Vet. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1016\/S0264-410X(03)00131-2","article-title":"Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys","volume":"21","author":"Morrill","year":"2003","journal-title":"Vaccine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.vaccine.2015.11.078","article-title":"Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates","volume":"34","author":"Pittman","year":"2016","journal-title":"Vaccine"},{"key":"ref_59","first-page":"95","article-title":"Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep","volume":"69","author":"Hunter","year":"2002","journal-title":"Onderstepoort J. Vet. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/infdis\/jir354","article-title":"Mucosal immunization of rhesus macaques with Rift Valley Fever MP-12 vaccine","volume":"204","author":"Morrill","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/infdis\/jir249","article-title":"Protection of MP-12-vaccinated rhesus macaques against parenteral and aerosol challenge with virulent rift valley fever virus","volume":"204","author":"Morrill","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"660","DOI":"10.4049\/jimmunol.89.5.660","article-title":"The development of a formalin-killed Rift Valley fever virus vaccine for use in man","volume":"89","author":"Randall","year":"1962","journal-title":"J. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4049\/jimmunol.93.2.293","article-title":"Immunization against rift valley fever virus: Studies on the immunogenicity of lyophilized formalin-inactivated vaccine","volume":"93","author":"Randall","year":"1964","journal-title":"J. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0264-410X(85)90061-1","article-title":"Rift Valley fever virus vaccine trial: Study of neutralizing antibody response in humans","volume":"3","author":"Niklasson","year":"1985","journal-title":"Vaccine"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0264-410X(86)90007-1","article-title":"Evaluation of a new Rift Valley fever vaccine: Safety and immunogenicity trials","volume":"4","author":"Meadors","year":"1986","journal-title":"Vaccine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/oxfordjournals.aje.a113471","article-title":"A rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up","volume":"116","author":"Kark","year":"1982","journal-title":"Am. J. Epidemiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0264-410X(85)90060-X","article-title":"A Rift Valley fever vaccine trial: 2. Serological response to booster doses with a comparison of intradermal versus subcutaneous injection","volume":"3","author":"Kark","year":"1985","journal-title":"Vaccine"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0264-410X(99)00218-2","article-title":"Immunogenicity of an inactivated Rift Valley fever vaccine in humans: A 12-year experience","volume":"18","author":"Pittman","year":"1999","journal-title":"Vaccine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.1995.53.405","article-title":"Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment","volume":"53","author":"Muller","year":"1995","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1016\/j.vaccine.2010.04.085","article-title":"Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep","volume":"28","author":"Dungu","year":"2010","journal-title":"Vaccine"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"857","DOI":"10.4102\/ojvr.v82i1.857","article-title":"Safety and immunogenicity of Onderstepoort Biological Products\u2019 Rift Valley fever Clone 13 vaccine in sheep and goats under field conditions in Senegal","volume":"82","author":"Lo","year":"2015","journal-title":"Onderstepoort J. Vet. Res."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Njenga, M.K., Njagi, L., Thumbi, S.M., Kahariri, S., Githinji, J., Omondi, E., Baden, A., Murithi, M., Paweska, J., and Ithondeka, P.M. (2015). Randomized controlled field trial to assess the immunogenicity and safety of rift valley fever clone 13 vaccine in livestock. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003550"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"779858","DOI":"10.3389\/fvets.2021.779858","article-title":"Safety, Immunogenicity and Antibody Persistence of Rift Valley Fever Virus Clone 13 Vaccine in Sheep, Goats and Cattle in Tanzania","volume":"8","author":"Sindato","year":"2021","journal-title":"Front. Vet. Sci."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Daouam, S., Ghzal, F., Naouli, Y., Tadlaoui, K.O., Ennaji, M.M., Oura, C., and El Harrak, M. (2016). Safety and immunogenecity of a live attenuated Rift Valley fever vaccine (CL13T) in camels. BMC Vet. Res., 12.","DOI":"10.1186\/s12917-016-0775-8"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"547","DOI":"10.6026\/97320630016547","article-title":"Comparative thermo-stability of two Rift Valley fever virus vaccine candidate CL13T with a recombinant arMP-12\u0394NSm21\/384","volume":"16","author":"Daouam","year":"2020","journal-title":"Bioinformation"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Makoschey, B., van Kilsdonk, E., Hubers, W.R., Vrijenhoek, M.P., Smit, M., Wichgers Schreur, P.J., Kortekaas, J., and Moulin, V. (2016). Rift Valley Fever Vaccine Virus Clone 13 Is Able to Cross the Ovine Placental Barrier Associated with Foetal Infections, Malformations, and Stillbirths. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004550"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"100070","DOI":"10.1016\/j.jvacx.2020.100070","article-title":"Safety and immunogenicity of the Rift Valley fever arMP-12 \u0394NSm21\/384 candidate vaccine in pregnant ewes","volume":"6","author":"Boumart","year":"2020","journal-title":"Vaccine X"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1016\/j.vaccine.2013.08.003","article-title":"Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves","volume":"31","author":"Morrill","year":"2013","journal-title":"Vaccine"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.vaccine.2012.10.118","article-title":"Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep","volume":"31","author":"Morrill","year":"2013","journal-title":"Vaccine"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.vaccine.2013.12.064","article-title":"Efficacy of a recombinant Rift Valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep","volume":"32","author":"Weingartl","year":"2014","journal-title":"Vaccine"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.4102\/ojvr.v86i1.1683","article-title":"Safety and immunogenicity of Rift Valley fever MP-12 and arMP-12\u0394NSm21\/384 vaccine candidates in goats (Capra aegagrus hircus) from Tanzania","volume":"86","author":"Nyundo","year":"2019","journal-title":"Onderstepoort J. Vet. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.vaccine.2019.01.067","article-title":"Safety and immunogenicity of a live attenuated Rift Valley Fever recombinant arMP-12\u0394NSm21\/384 vaccine candidate for sheep, goats and calves","volume":"37","author":"Boumart","year":"2019","journal-title":"Vaccine"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3389\/fmicb.2015.00651","article-title":"MP-12 virus containing the clone 13 deletion in the NSs gene prevents lethal disease when administered after Rift Valley fever virus infection in hamsters","volume":"6","author":"Gowen","year":"2015","journal-title":"Front. Microbiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6634","DOI":"10.1016\/j.vaccine.2017.10.036","article-title":"Attenuation and protective efficacy of Rift Valley fever phlebovirus rMP12-GM50 strain","volume":"35","author":"Ly","year":"2017","journal-title":"Vaccine"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1016\/j.vaccine.2014.07.037","article-title":"Comparative efficacy of two next-generation Rift Valley fever vaccines","volume":"32","author":"Kortekaas","year":"2014","journal-title":"Vaccine"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1128\/JVI.02501-07","article-title":"Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals","volume":"82","author":"Bird","year":"2008","journal-title":"J. Virol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"12901","DOI":"10.1128\/JVI.06046-11","article-title":"Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep","volume":"85","author":"Bird","year":"2011","journal-title":"J. Virol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Smith, D.R., Johnston, S.C., Piper, A., Botto, M., Donnelly, G., Shamblin, J., Albari\u00f1o, C.G., Hensley, L.E., Schmaljohn, C., and Nichol, S.T. (2018). Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006474"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1111\/tbed.14415","article-title":"Safety study of Rift Valley Fever human vaccine candidate (DDVax) in mosquitoes","volume":"69","author":"Campbell","year":"2021","journal-title":"Transbound. Emerg. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"10883","DOI":"10.1128\/JVI.00961-14","article-title":"Creation of Rift Valley fever viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging","volume":"88","author":"Oreshkova","year":"2014","journal-title":"J. Virol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.vaccine.2015.01.077","article-title":"Four-segmented Rift Valley fever virus induces sterile immunity in sheep after a single vaccination","volume":"33","author":"Kant","year":"2015","journal-title":"Vaccine"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.vaccine.2017.04.024","article-title":"Four-segmented Rift Valley fever virus-based vaccines can be applied safely in ewes during pregnancy","volume":"35","author":"Kant","year":"2017","journal-title":"Vaccine"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41541-020-00212-4","article-title":"Safety and efficacy of four-segmented Rift Valley fever virus in young sheep, goats and cattle","volume":"5","author":"Oreshkova","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41541-020-00271-7","article-title":"A single vaccination with four-segmented rift valley fever virus prevents vertical transmission of the wild-type virus in pregnant ewes","volume":"6","author":"Oymans","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1016\/j.vaccine.2005.08.034","article-title":"Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus","volume":"24","author":"Spik","year":"2006","journal-title":"Vaccine"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1743-422X-6-6","article-title":"Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs","volume":"6","author":"Lagerqvist","year":"2009","journal-title":"Virol. J."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Bhardwaj, N., Heise, M.T., and Ross, T.M. (2010). Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing Gn protects mice against Rift Valley fever virus. PLoS Negl. Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000725"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1016\/j.vaccine.2010.02.018","article-title":"Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR(\u2212\/\u2212) mice induced by different DNA vaccination regimens","volume":"28","author":"Lorenzo","year":"2010","journal-title":"Vaccine"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13567-018-0516-z","article-title":"Efficacy of different DNA and MVA prime-boost vaccination regimens against a Rift Valley fever virus (RVFV) challenge in sheep 12 weeks following vaccination","volume":"49","author":"Lorenzo","year":"2018","journal-title":"Vet. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41541-018-0052-x","article-title":"A Rift Valley fever virus Gn ectodomain-based DNA vaccine induces a partial protection not improved by APC targeting","volume":"3","author":"Chrun","year":"2018","journal-title":"NPJ Vaccines"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1021\/acs.molpharmaceut.0c00054","article-title":"A DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Virus","volume":"17","author":"Borrego","year":"2020","journal-title":"Mol. Pharm."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10529-020-02816-1","article-title":"Microencapsulated plasmids expressing Gn and Gc glycoproteins of Rift Valley Fever virus enhance humoral immune response in mice","volume":"42","author":"Selina","year":"2020","journal-title":"Biotechnol. Lett."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1016\/j.vaccine.2006.06.041","article-title":"Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever","volume":"24","author":"Wallace","year":"2006","journal-title":"Vaccine"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fvets.2020.00256","article-title":"Protection of Cattle Elicited Using a Bivalent Lumpy Skin Disease Virus-Vectored Recombinant Rift Valley Fever Vaccine","volume":"7","author":"Wallace","year":"2020","journal-title":"Front. Vet. Sci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1128\/CVI.00182-09","article-title":"A complex adenovirus-vectored vaccine against Rift Valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity","volume":"16","author":"Holman","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1016\/j.vaccine.2010.04.048","article-title":"Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector","volume":"28","author":"Kortekaas","year":"2010","journal-title":"Vaccine"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"14926","DOI":"10.1073\/pnas.1112149108","article-title":"Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice","volume":"108","author":"Papin","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/1743-422X-10-349","article-title":"Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice","volume":"10","author":"Warimwe","year":"2013","journal-title":"Virol. J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"20617","DOI":"10.1038\/srep20617","article-title":"Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever","volume":"6","author":"Warimwe","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41541-019-0138-0","article-title":"Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats","volume":"4","author":"Stedman","year":"2019","journal-title":"NPJ Vaccines"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.vaccine.2016.03.061","article-title":"Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle","volume":"34","author":"Dulal","year":"2016","journal-title":"Vaccine"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Gil, E., Lorenzo, G., Hevia, E., Borrego, B., Eiden, M., Groschup, M., Gilbert, S.C., and Brun, A. (2013). A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection. PLoS Negl. Trop. Dis., 7.","DOI":"10.1371\/journal.pntd.0002309"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.antiviral.2014.05.020","article-title":"Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs","volume":"108","author":"Busquets","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Gil, E., Moreno, S., Ortego, J., Borrego, B., Lorenzo, G., and Brun, A. (2020). MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses. Vaccines, 8.","DOI":"10.3390\/vaccines8010082"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41541-020-00218-y","article-title":"A protective bivalent vaccine against Rift Valley fever and bluetongue","volume":"5","author":"Moreno","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12985-017-0811-8","article-title":"An equine herpesvirus type 1 (EHV-1) vector expressing Rift Valley fever virus (RVFV) Gn and Gc induces neutralizing antibodies in sheep","volume":"14","author":"Said","year":"2017","journal-title":"Virol. J."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1128\/CVI.00220-10","article-title":"Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine","volume":"17","author":"Soi","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Zhang, S., Hao, M., Feng, N., Jin, H., Yan, F., Chi, H., Wang, H., Han, Q., Wang, J., and Wong, G. (2019). Genetically Modified Rabies Virus Vector-Based Rift Valley Fever Virus Vaccine is Safe and Induces Efficacious Immune Responses in Mice. Viruses, 11.","DOI":"10.3390\/v11100919"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1016\/j.vaccine.2012.03.027","article-title":"Efficacy of three candidate Rift Valley fever vaccines in sheep","volume":"30","author":"Kortekaas","year":"2012","journal-title":"Vaccine"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1089\/vbz.2014.1650","article-title":"A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep","volume":"14","author":"Faburay","year":"2014","journal-title":"Vector-BorneZoonotic Dis."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"27719","DOI":"10.1038\/srep27719","article-title":"A Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Confers Full Protection against Rift Valley Fever Challenge in Sheep","volume":"6","author":"Faburay","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Wilson, W.C., Faburay, B., Trujillo, J.D., Ragan, I., Sunwoo, S.Y., Morozov, I., Shivanna, V., Balogh, A., Urbaniak, K., and McVey, D.S. (2021). Preliminary Evaluation of a Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Providing Full Protection against Heterologous Virulent Challenge in Cattle. Vaccines, 9.","DOI":"10.3390\/vaccines9070748"},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Wichgers Schreur, P.J., Tacken, M., Gutjahr, B., Keller, M., van Keulen, L., Kant, J., van de Water, S., Lin, Y., Eiden, M., and Rissmann, M. (2021). Vaccine Efficacy of Self-Assembled Multimeric Protein Scaffold Particles Displaying the Glycoprotein Gn Head Domain of Rift Valley Fever Virus. Vaccines, 9.","DOI":"10.3390\/vaccines9030301"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1017\/S0950268808001696","article-title":"An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus","volume":"137","author":"Heise","year":"2009","journal-title":"Epidemiol. Infect."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.virol.2007.04.014","article-title":"Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins","volume":"366","author":"Gorchakov","year":"2007","journal-title":"Virology"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Oreshkova, N., van Keulen, L., Kant, J., Moormann, R.J., and Kortekaas, J. (2013). A single vaccination with an improved nonspreading Rift Valley fever virus vaccine provides sterile immunity in lambs. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0077461"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1128\/JVI.07104-11","article-title":"Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge","volume":"86","author":"Dodd","year":"2012","journal-title":"J. Virol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Murakami, S., Terasaki, K., Ramirez, S.I., Morrill, J.C., and Makino, S. (2014). Development of a novel, single-cycle replicable rift valley Fever vaccine. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0002746"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"17097","DOI":"10.1038\/s41598-018-35472-7","article-title":"A single-cycle replicable Rift Valley fever phlebovirus vaccine carrying a mutated NSs confers full protection from lethal challenge in mice","volume":"8","author":"Terasaki","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"12622","DOI":"10.1128\/JVI.00841-11","article-title":"Creation of a nonspreading Rift Valley fever virus","volume":"85","author":"Kortekaas","year":"2011","journal-title":"J. Virol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.virol.2008.12.012","article-title":"Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus","volume":"385","author":"Lagerqvist","year":"2009","journal-title":"Virology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.virol.2009.11.001","article-title":"A replication-incompetent Rift Valley fever vaccine: Chimeric virus-like particles protect mice and rats against lethal challenge","volume":"397","author":"Mandell","year":"2010","journal-title":"Virology"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fvets.2020.00062","article-title":"Immunogenicity Assessment of Rift Valley Fever Virus Virus-Like Particles in BALB\/c Mice","volume":"7","author":"Li","year":"2020","journal-title":"Front. Vet. Sci."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.vaccine.2015.12.030","article-title":"Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans","volume":"34","author":"Pittman","year":"2016","journal-title":"Vaccine"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.antiviral.2013.03.009","article-title":"Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge","volume":"98","author":"Gowen","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Whiteley, W.N., Ip, S., Cooper, J.A., Bolton, T., Keene, S., Walker, V., Denholm, R., Akbari, A., Omigie, E., and Hollings, S. (2022). Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England. PLoS Med., 19.","DOI":"10.1371\/journal.pmed.1003926"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"100274","DOI":"10.1016\/j.lanepe.2021.100274","article-title":"Most cases of Thrombosis and Thrombocytopenia Syndrome (TTS) post ChAdOx-1 nCov-19 are Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT)","volume":"12","author":"Makris","year":"2022","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"11371","DOI":"10.1073\/pnas.93.21.11371","article-title":"Alphavirus-based expression vectors: Strategies and applications","volume":"93","author":"Frolov","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1128\/JVI.75.8.3706-3718.2001","article-title":"Role of alpha\/beta interferon in Venezuelan equine encephalitis virus pathogenesis: Effect of an attenuating mutation in the 5\u2032 untranslated region","volume":"75","author":"White","year":"2001","journal-title":"J. Virol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Mellado","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1016\/j.vaccine.2009.12.062","article-title":"Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge","volume":"28","author":"Kortekaas","year":"2010","journal-title":"Vaccine"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.antiviral.2014.03.008","article-title":"One Health approach to Rift Valley fever vaccine development","volume":"106","author":"Kortekaas","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e002694","DOI":"10.1136\/bmjgh-2020-002694","article-title":"Rift valley fever: Diagnostic challenges and investment needs for vaccine development","volume":"5","author":"Petrova","year":"2020","journal-title":"BMJ Glob. Health"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"m4709","DOI":"10.1136\/bmj.m4709","article-title":"Covid-19: Moderna applies for US and EU approval as vaccine trial reports 94.1% efficacy","volume":"371","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-021-01480-7","article-title":"BNT162b2 mRNA COVID-19 Vaccine: First Approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Blakney, A.K., Ip, S., and Geall, A.J. (2021). An Update on Self-Amplifying mRNA Vaccine Development. Vaccines, 9.","DOI":"10.3390\/vaccines9020097"},{"key":"ref_148","first-page":"117","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2021","journal-title":"Gene"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1353\/eas.2013.0009","article-title":"Sub-Saharan Africa electricity supply inadequacy: Implications","volume":"29","author":"Kaseke","year":"2013","journal-title":"East. Afr. Soc. Sci. Res. Rev."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Stitz, L., Vogel, A., Schnee, M., Voss, D., Rauch, S., Mutzke, T., Ketterer, T., Kramps, T., and Petsch, B. (2017). A thermostable messenger RNA based vaccine against rabies. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0006108"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/11\/1794\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:02:38Z","timestamp":1760144558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/11\/1794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,25]]},"references-count":150,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["vaccines10111794"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10111794","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,25]]}}}